The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10317 malaria professionals are enjoying the free benefits of MalariaWorld today

first-in-human trial

Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial

February 11, 2020 - 16:26 -- Open Access
Author(s): 
Antje Blank, Kristin Fürle, Hermann Bujard, et al.
Reference: 
npj Vaccines 5, 10 (2020)

A vaccine remains a priority in the global fight against malaria. Here, we report on a single-center, randomized, double-blind, placebo and adjuvant-controlled, dose escalation phase 1a safety and immunogenicity clinical trial of full-length Plasmodium falciparum merozoite surface protein 1 (MSP1) in combination with GLA-SE adjuvant. Thirty-two healthy volunteers were vaccinated at least three times with MSP1 plus adjuvant, adjuvant alone, or placebo (24:4:4) to evaluate the safety and immunogenicity.

Subscribe to RSS - first-in-human trial